Evidence map›Paper›PMID 31218445›Full record

ArticleEuropean archives of psychiatry and clinical neuroscience2020

Three plasma metabolites in elderly patients differentiate mild cognitive impairment and Alzheimer's disease: a pilot study.

Alana C Costa, Helena P G Joaquim, Orestes V Forlenza, Wagner F Gattaz, Leda L Talib

Abstract read
PubMed Publisher
In one paragraph

Article in European archives of psychiatry and clinical neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Metabolomics: a new frontier in neurodegenerative disease biomarker discovery.Metabolomics : Official journal of the Metabolomic Society · 2025
    Review
  2. Article
  3. Artificial intelligence for biomarker discovery in Alzheimer's disease and dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023
    Review
  4. Article
  5. Integrative metabolomics-genomics approach reveals key metabolic pathways and regulators of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 2 countries.

Alana C CostaLaboratório de Neurociências (LIM-27), Departamento e Instituto de Psiquiatria, Faculdade de Medicina da Universidade de São Paulo, Rua Dr. Ovídio Pires de Campos, 785, 3º andar, Sao Paulo, 05403-010, Brazil.
Helena P G JoaquimLaboratório de Neurociências (LIM-27), Departamento e Instituto de Psiquiatria, Faculdade de Medicina da Universidade de São Paulo, Rua Dr. Ovídio Pires de Campos, 785, 3º andar, Sao Paulo, 05403-010, Brazil.
Orestes V ForlenzaLaboratório de Neurociências (LIM-27), Departamento e Instituto de Psiquiatria, Faculdade de Medicina da Universidade de São Paulo, Rua Dr. Ovídio Pires de Campos, 785, 3º andar, Sao Paulo, 05403-010, Brazil.
Wagner F GattazLaboratório de Neurociências (LIM-27), Departamento e Instituto de Psiquiatria, Faculdade de Medicina da Universidade de São Paulo, Rua Dr. Ovídio Pires de Campos, 785, 3º andar, Sao Paulo, 05403-010, Brazil.
Leda L TalibLaboratório de Neurociências (LIM-27), Departamento e Instituto de Psiquiatria, Faculdade de Medicina da Universidade de São Paulo, Rua Dr. Ovídio Pires de Campos, 785, 3º andar, Sao Paulo, 05403-010, Brazil. ledatalib@gmail.com.ORCID http://orcid.org/0000-0001-5866-1993
National Council for Scientific and Technological Development · BR

Funding

Fundação de Amparo à Pesquisa do Estado de São Paulo 2013/103509Fundação de Amparo à Pesquisa do Estado de São Paulo 2014/20913-3Fundação de Amparo à Pesquisa do Estado de São Paulo 2014/50873-3
6 · The paper itself

Abstract

The metabolomic profile of patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI) may suggest potential diagnostic biomarkers and provide information on the pathophysiology of dementia. Our aim was to quantify plasmatic metabolites of AD patients, MCI and controls. We investigated the metabolomic profile-using the AbsoluteIDQ®p180 assay-of 79 older adults with primary cognitive impairment (34 AD and 20 MCI) and 25 healthy elders (controls). A cluster analysis revealed that a combination C12-DC, C12 and PCaaC26:0 could differentiate the patients according to diagnostic. Future studies should combine metabolomic profiles with other biomarkers to identify diagnostic groups.

Indexed as

MetabolomeAgedAged, 80 and overAgingAlzheimer DiseaseBiomarkersCognitive DysfunctionDiagnosis, DifferentialFemaleHumansMaleMetabolomicsPilot ProjectsBiomarkersAlzheimer’s diseaseBiomarkersMild cognitive impairmentPlasma metabolites

Identifiers

PMID31218445
OpenAlexW2952961942

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.